London Daily

Focus on the big picture.
Tuesday, Nov 25, 2025

Covid vaccines: EU tussle with UK over AstraZeneca escalates

Covid vaccines: EU tussle with UK over AstraZeneca escalates

"This is not about EU v UK. This is a problem with AstraZeneca," claimed an EU diplomat this morning.

He and I were discussing the latest thorny chapter in EU efforts to secure the Oxford-AstraZeneca jabs written into the bloc's contract with the Anglo-Swedish pharmaceutical company.

The debate is now focused on a production plant in the Netherlands, manufacturing AstraZeneca vaccines.

Boris Johnson is calling a number of EU leaders ahead of their meeting on Thursday, to try to ensure that AstraZeneca jabs - or components of jabs - produced in the Halix factory won't be blocked by the EU and kept from the UK.

EU officials say there has been no formal request by the UK for an export from Halix - yet.

But the already-existing cross-Channel strains surrounding the vaccine are infamous by now.

The EU insists AstraZeneca made different and contradictory promises to Brussels and to the UK in their respective contracts, signed last year.

They say the EU-AstraZeneca contract promised:

*  to ensure vaccine deliveries to the EU using production facilities in both the EU and UK

*  an assurance from AstraZeneca that it had no other contracts which could get in the way of it fulfilling its commitments to the EU

"Yet at the same time, AstraZeneca appears to have promised the UK priority for the first X million doses - using production facilities in the EU, as well as the UK. This doesn't add up. Though this isn't the UK's fault," concluded the first EU diplomat I spoke to this morning.

"If you include the 20 million AZ doses promised to us already in December, that's 120 million jabs we expected from AstraZeneca by the end of this month. If the EU sees 30 million of those, we'll count ourselves lucky," the diplomat snorted.

AstraZeneca denies that it is failing to honour its contract with the EU. It says the contract commits the company to making the "best reasonable efforts" - which, it says, it is doing, faced with production challenges.

Post-Brexit tensions


EU frustration with AstraZeneca has been boiling for months now.

And - whatever protestations you hear in Brussels to the contrary - there has been political spillage into EU attitudes towards the UK.

Don't forget: when the AZ delivery row with Brussels first exploded in January, the EU was still smarting from Brexit, bruising trade negotiations with the UK and ongoing bilateral frustrations around implementing the Brexit deal on Northern Ireland.

That seems to have given an extra dimension to the ire of many an EU politician, when AstraZeneca continued (until very recently) to apparently seamlessly deliver jabs to the UK, even while it defaulted significantly on pledges made to the EU.

UK officials point to jabs and digs they say have been made by EU figures. Attempts, they say, to undermine Britain's comparatively speedy and successful vaccine rollout.

EU leaders, like France's President Emmanuel Macron, are accused by some in the UK of seeking to undermine the Oxford-AstraZeneca jab because of its links with Britain.

Back in January Mr Macron described the AZ jab as "quasi-ineffective" in the over-65s. He then changed his mind, as the French government later approved the vaccine for the older population.

Others in the UK say they didn't appreciate it when the EU appeared to question the safety of the UK medical regulatory body granting emergency approval to the Oxford-AstraZeneca vaccine, while the EU chose a slightly longer approval process.


But EU politicians point the finger at the UK too. They accuse UK politicians and media of trying to score political points against Brussels, post-Brexit, using the vaccine rollout.

"The UK never dwells on the fact that the US has yet to approve the AstraZeneca jab," an EU official complained to me. "The criticisms are just about us (the EU)."

"There's so much post-Brexit triumphalism in the UK," complained a representative of another EU country.

"They often claim their vaccine programme would never have been such a success if it hadn't been for Brexit. But that's not true. Even if the UK had stayed a member state, it could have gone its own way over vaccines."

UK diplomats point to what they describe as the "more measured tones" of Prime Minister Johnson as regards vaccines and the EU. They insist that this is key as, they say, vaccine plans come from the "highest levels" of government.

As for the Halix plant in the Netherlands, the EU and Downing Street appear to be seeking some kind of compromise.

I'm told that talks are ongoing. A sign, say UK diplomats, that both sides are engaged in finding a solution.

The diplomats insist it's not in anyone's interest to have vaccines or vaccine components "sitting in a warehouse" when the aim - on both sides of the Channel - is to get needles into arms.


EU export ban?


The Halix plant in the Netherlands hasn't yet received an EU licence to deliver vaccines or components of vaccines to member states, although the European Commission says the green light is expected soon.

It's not clear what happened with the delivery of 250,000 AstraZeneca vaccines destined for Australia that Italy impounded a few weeks ago, with European Commission approval.

Current EU rules allow member states to bloc vaccine exports leaving the EU, if the company producing the doses has failed to fulfil its contract with the EU.

Officials in Brussels say right now that only applies to AstraZeneca.

Now the European Commission wants to get even tougher - possibly blocking exports of any vaccine produced in the EU, destined for a country outside that has its own vaccine production capabilities and a vaccine rollout considerably ahead of the EU.

Without mentioning the UK specifically, this would certainly apply to the UK.

EU leaders aren't united in favour of this latest Commission proposal, as is likely to become apparent during their summit on Thursday. Most say they would prefer a negotiated solution.

On Monday, Ireland's Prime Minister (Taoiseach) Micheál Martin said any EU restrictions on vaccine exports would be a "retrograde step" that could undermine the supply of raw materials for vaccine production.

Chief European Commission spokesman Eric Mamer said Brussels was not seeking to block exports, it was aiming to secure the vaccine supply it was promised. He said the EU was currently considering which tools to use to achieve that.

The Commission, meanwhile, has been blamed by many inside and outside the EU for making mistakes over EU vaccine procurement and production capacity.

It's been on the defensive of late. Attempting to promote the EU's reputation as the world's biggest single exporter of vaccines, it says 40 million doses were exported to 31 countries in just six weeks. With the biggest beneficiary to date being the UK which, says the Commission, received 10 million doses in that period.

"If you look at it that way," an EU diplomat said to me, "we (the EU) have contributed to the UK's vaccine success.

"If we are to find a solution over the Halix plant, it will have to involve reciprocity. So far we (the EU) have yet to receive a single dose produced in the UK, even though their rollout is so very far ahead of ours. Maybe the government could sell it as 'helping our European friends as we've done in the past'."

Of course, Boris Johnson is under huge public pressure to continue the successful vaccine rollout at home.

Political pressure is building heavily on Brussels and individual EU governments to improve their vaccine rollout. Fast.

The EU lags far behind the UK and the US, just as a pernicious third wave of the pandemic is hitting a number of countries.

Germany on Monday is considering extending and even tightening lockdown restrictions. Italy will shut down the country for three days over Easter. Central and Eastern Europe have some of the highest coronavirus-linked death rates in the world.

The European Commission still insists the majority of adults in the EU can be vaccinated by the end of summer; that vaccine supply in the EU will increase exponentially come April.

But the EU vaccine challenge is not solely supply. It's demand - or trust - too.

Many in the EU were always more vaccine-wary than their UK counterparts.

EU leaders' on-again-off-again relationship with the AstraZeneca jab hasn't helped.

The latest scare centred around fears of a side-effect of blood clots in the brain.

The European Medicines Agency ruled the vaccine safe after an investigation, but the incident set vaccine rollouts back further in at least 15 European countries.

It seems to have undermined already patchy public confidence too.

A new survey by YouGov suggests that fewer than half of Spaniards, Italians, French and Germans judge the AstraZeneca vaccine to be safe, despite evidence to the contrary.

That said, the EU countries that most rely on the AstraZeneca vaccine for their populations are the countries of Central and Eastern Europe, including Austria.

At the EU leaders' summit on Thursday they'll be pressing for solutions.


Why do new variants of Covid-19 keep appearing? Laura Foster explains


Newsletter

Related Articles

0:00
0:00
Close
UK Economy Stalls as Reeves Faces First Budget Test
UK Economy’s Weak Start Adds Pressure on Prime Minister Starmer
UK Government Acknowledges Billionaire Exodus Amid Tax Rise Concerns
UK Budget 2025: Markets Brace as Chancellor Faces Fiscal Tightrope
UK Unveils Strategic Plan to Secure Critical Mineral Supply Chains
UK Taskforce Calls for Radical Reset of Nuclear Regulation to Cut Costs and Accelerate Build
UK Government Launches Consultation on Major Overhaul of Settlement Rules
Google Struggles to Meet AI Demand as Infrastructure, Energy and Supply-Chain Gaps Deepen
Car Parts Leader Warns Europe Faces Heavy Job Losses in ‘Darwinian’ Auto Shake-Out
Arsenal Move Six Points Clear After Eze’s Historic Hat-Trick in Derby Rout
Wealthy New Yorkers Weigh Second Homes as the ‘Mamdani Effect’ Ripples Through Luxury Markets
Families Accuse OpenAI of Enabling ‘AI-Driven Delusions’ After Multiple Suicides
UK Unveils Critical-Minerals Strategy to Break China Supply-Chain Grip
Taylor Swift’s “The Fate of Ophelia” Extends U.K. No. 1 Run to Five Weeks
UK VPN Sign-Ups Surge by Over 1,400 % as Age-Verification Law Takes Effect
Former MEP Nathan Gill Jailed for Over Ten Years After Taking Pro-Russia Bribes
Majority of UK Entrepreneurs Regard Government as ‘Anti-Business’, Survey Shows
UK’s Starmer and US President Trump Align as Geneva Talks Probe Ukraine Peace Plan
UK Prime Minister Signals Former Prince Andrew Should Testify to US Epstein Inquiry
Royal Navy Deploys HMS Severn to Shadow Russian Corvette and Tanker Off UK Coast
China’s Wedding Boom: Nightclubs, Mountains and a Demographic Reset
Fugees Founding Member Pras Michel Sentenced to 14 Years in High-Profile US Foreign Influence Case
WhatsApp’s Unexpected Rise Reshapes American Messaging Habits
United States: Judge Dressed Up as Elvis During Hearings – and Was Forced to Resign
Johnson Blasts ‘Incoherent’ Covid Inquiry Findings Amid Report’s Harsh Critique of His Government
Lord Rothermere Secures £500 Million Deal to Acquire Telegraph Titles
Maduro Tightens Security Measures as U.S. Strike Threat Intensifies
U.S. Envoys Deliver Ultimatum to Ukraine: Sign Peace Deal by Thursday or Risk Losing American Support
Zelenskyy Signals Progress Toward Ending the War: ‘One of the Hardest Moments in History’ (end of his business model?)
U.S. Issues Alert Declaring Venezuelan Airspace a Hazard Due to Escalating Security Conditions
The U.S. State Department Announces That Mass Migration Constitutes an Existential Threat to Western Civilization and Undermines the Stability of Key American Allies
Students Challenge AI-Driven Teaching at University of Staffordshire
Pikeville Medical Center Partners with UK’s Golisano Children’s Network to Expand Pediatric Care
Germany, France and UK Confirm Full Support for Ukraine in US-Backed Security Plan
UK Low-Traffic Neighbourhoods Face Rising Backlash as Pandemic Schemes Unravel
UK Records Coldest Night of Autumn as Sub-Zero Conditions Sweep the Country
UK at Risk of Losing International Doctors as Workforce Exodus Grows, Regulator Warns
ASU Launches ASU London, Extending Its Innovation Brand to the UK Education Market
UK Prime Minister Keir Starmer to Visit China in January as Diplomatic Reset Accelerates
Google Launches Voluntary Buyouts for UK Staff Amid AI-Driven Company Realignment
UK braces for freezing snap as snow and ice warnings escalate
Majority of UK Novelists Fear AI Could Displace Their Work, Cambridge Study Finds
UK's Carrier Strike Group Achieves Full Operational Capability During NATO Drill in Mediterranean
Trump and Mamdani to Meet at the White House: “The Communist Asked”
Nvidia Again Beats Forecasts, Shares Jump in After-Hours Trading
Wintry Conditions Persist Along UK Coasts After Up to Seven Centimetres of Snow
UK Inflation Eases to 3.6 % in October, Opening Door for Rate Cut
UK Accelerates Munitions Factory Build-Out to Reinforce Warfighting Readiness
UK Consumer Optimism Plunges Ahead of November Budget
A Decade of Innovation Stagnation at Apple: The Cook Era Critique
×